ANGO angiodynamics.com: Company Value to Revenue

Official company branding of AngioDynamics (ANGO)

The EV/Revenue multiple dynamics for AngioDynamics, Inc. (ANGO) demonstrate a period of asset restructuring under management striving for profitability. The value of 1319.32 reflects this status. The fundamental basis is established by complex oncology systems that create high switching costs for providers, as well as steady clinical demand for vascular consumables, which ensures the predictability of the company's cash flows.

angiodynamics.com (ANGO): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

ANGO (AngioDynamics Inc.): analytical breakdowns and indicator data

- current quotes and average value forecast:
Fundamental company valuation:ANGO - angiodynamics.com
Manufactured products of AngioDynamics Corp

AngioDynamics, Inc. (ANGO) specializes in the production of high-tech medical instrumentation. The enterprise value-to-revenue ratio, adjusted for debt, allows for an assessment of the asset's market value excluding leverage. By analyzing the EV/Sales chart, an investor determines the efficiency of operational monetization. The implementation of eco-friendly packaging and sterilization optimization directly impact margins and capital expenditures. The stable trajectory of this indicator confirms the fundamental resilience of the price.

Competitor analysis

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|EV/Sales Multiple cerus.com CERS|teknova.com - EV/Sales Multiple|Enterprise Value-to-Sales Ratio Monogram Technologies Inc. (MGRM)|Sharps Technology, Inc. (STSS) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple